Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Axsome Therapeutics Inc. investors can proceed with a proposed class action alleging the drugmaker misled them about a ...

Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...

Axsome Therapeutics (AXSM) stock gains as solriamfetol, its experimental drug for ADHD succeeds in a Phase 3 trial. Read more ...

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...